Professor Nick Lemoine
Director, CRUK Barts Centre; Medical Director, NIHR Clinical Research Network
I am the Director of Barts Cancer Institute. My groups’ primary research interests are in the genomics and molecular pathology of pancreatic cancer and the development of oncolytic virotherapy.
Professor Jack Cuzick
Director, Wolfson Institute of Preventive Medicine
I am the Director of Wolfson Institute of Preventive Medicine and also Head of Centre for Cancer Prevention. My current interests are in cancer epidemiology and clinical trials, with special interest in prevention and screening.
Professor Jude Fitzgibbon
Professor of Personalised Cancer Medicine
My research group works on molecular pathology, genetics and progression of leukaemia and lymphomas, aiming to improve on current diagnostic, prognostic and treatment strategies.
Professor Kairbaan Hodivala-Dilke
Deputy Institute Director, Professor of the Tumour Microenvironment
Cancers are composed of both tumour and stromal compartments. We are interested in understanding the molecular basis of how the tumour stroma contributes to tumour growth, therapy resistance and spread, in various solid tumours including lung cancers, pancreatic cancer and melanoma.
Professor John F. Marshall
Professor of Tumour Biology
For over 25 years I have studied the biology of tumour invasion with a particular interest in the roles of the adhesion molecules expressed on the cell surface that mediate this process. Our group concentrates on the study of integrins that are the principal family of adhesion molecules that mediate interaction between cells and the extracellular matrix (ECM).
Professor Tyson V. Sharp
Professor of Cellular and Molecular Biology
My group’s work focuses on the role of the tumour suppressor protein LIMD1 and its family members Ajuba and WTIP and how their deregulation in normal tissue contributes to the development of lung, renal and breast cancer.
Professor John Gribben
Professor of Medical Oncology
My group focuses on immunological approaches to the treatment of haematological cancers. My primary research interests include the immunotherapy of cancer (including stem cell transplantation), the identification of B-cell-tumour antigens; and the detection and treatment of minimal residual disease in leukaemia and lymphoma.
Professor Peter Schmid
Professor of Cancer Medicine
My research interests primarily focus on breast cancer, lung cancer and early drug development. I oversee clinical and translational research on immune checkpoint inhibitors and other immune strategies.